Next Article in Journal
Individual versus Combinatorial Effects of Silicon, Phosphate, and Iron Deficiency on the Growth of Lowland and Upland Rice Varieties
Next Article in Special Issue
Sympathetic Nerve Hyperactivity in the Spleen: Causal for Nonpathogenic-Driven Chronic Immune-Mediated Inflammatory Diseases (IMIDs)?
Previous Article in Journal
An Anion Conductance, the Essential Component of the Hydroxyl-Radical-Induced Ion Current in Plant Roots
Previous Article in Special Issue
Transcriptional Responses in the Murine Spleen after Toxoplasma gondii Infection: Inflammasome and Mucus-Associated Genes

Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis

Department of Hematology-Oncology, Hanyang University Hanmaeum Changwon Hospital, Changwon 51497, Korea
Division of Hematology-Oncology, Department of Internal Medicine, Hanyang University College of Medicine, Hanyang University Hospital, 222-1, Seongdong-Gu Wangsimni-Ro, Seoul 04763, Korea
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(3), 898;
Received: 8 February 2018 / Revised: 16 March 2018 / Accepted: 17 March 2018 / Published: 18 March 2018
Myelofibrosis (MF) is a clinical manifestation of chronic BCR-ABL1-negative chronic myeloproliferative neoplasms. Splenomegaly is one of the major clinical manifestations of MF and is directly linked to splenic extramedullary hematopoiesis (EMH). EMH is associated with abnormal trafficking patterns of clonal hematopoietic cells due to the dysregulated bone marrow (BM) microenvironment leading to progressive splenomegaly. Several recent data have emphasized the role of several cytokines for splenic EMH. Alteration of CXCL12/CXCR4 pathway could also lead to splenic EMH by migrated clonal hematopoietic cells from BM to the spleen. Moreover, low Gata1 expression was found to be significantly associated with the EMH. Several gene mutations were found to be associated with significant splenomegaly in MF. In recent data, JAK2 V617F homozygous mutation was associated with a larger spleen size. In other data, CALR mutations in MF were signigicantly associated with longer larger splenomegaly-free survivals than others. In addition, MF patients with ≥1 mutations in AZXL1, EZH1 or IDH1/2 had significantly low spleen reduction response in ruxolitinib treatment. Developments of JAK inhibitors, such as ruxolitinib, pacritinib, momelotinib, and febratinib enabled the effective management in MF patients. Especially, significant spleen reduction responses of the drugs were demonstrated in several randomized clinical studies, although those could not eradicate allele burdens of MF. View Full-Text
Keywords: splenomegaly; extramedullary hematopoiesis; myelofibrosis splenomegaly; extramedullary hematopoiesis; myelofibrosis
Show Figures

Figure 1

MDPI and ACS Style

Song, M.-K.; Park, B.-B.; Uhm, J.-E. Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis. Int. J. Mol. Sci. 2018, 19, 898.

AMA Style

Song M-K, Park B-B, Uhm J-E. Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis. International Journal of Molecular Sciences. 2018; 19(3):898.

Chicago/Turabian Style

Song, Moo-Kon, Byeong-Bae Park, and Ji-Eun Uhm. 2018. "Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis" International Journal of Molecular Sciences 19, no. 3: 898.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop